SPATS2 and hepatocellular carcinoma: Then, in MHCC-97H and HCC-LM3, two HCC cell lines with the highest SPATS2 expression, we designed two independent shRNAs for each cell line to silence SPATS2 with knockdown efficiencies>70% (Figure 1B).